BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 09, 2009
 |  BioCentury  |  Finance

EPS watch

EPS watch

Company 4Q08 EPS est 4Q08 EPS actual Outcome Growth from 4Q07 2/6 cls Wk chg %chg Mcap chg 2/6 Mcap
Biogen Idec (NASDAQ:BIIB) $0.93 $0.93 Met 4% $52.48 $3.83 8% $1,116.6 $15,299.6
4Q08 revenues were $1.1B, a 20% increase from $893M in 4Q07 and meetng the Street's forecast. Fourth quarter sales of Avonex interferon beta-1a were $565.8M, up 13% from $502.5M in 4Q07. Fourth quarter U.S. sales of Rituxan for rheumatoid arthritis (RA) and non-Hodgkin's lymphoma (NHL), as recorded by partner Genentech (NYSE:DNA), rose 14% to $677M. Biogen reported $303M in 4Q Rituxan revenues, up 20%. Global sales of Tysabri natalizumab, which is partnered with Elan (NYSE:ELN), were $218M. Biogen recognized $155.6M in Tysabri revenue, up 74% from $89.6M in 4Q07. The partners market the humanized mAb against integrin alpha(4) to treat multiple sclerosis (MS) and Crohn's disease. Biogen said it expects 2009 non-GAAP diluted EPS...

Read the full 936 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >